Glycaemic trajectories and the role of interleukin 18 as a surrogate biomarker for cardiovascular risk in persons with tuberculosis
Journal of Kenya Assocation of Physicians · 08.04.2026 · 8 (1) · 13-30
DOI: 10.4314/jkap.v8i1.3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Kenya Assocation of Physicians, online erschienen am 08.04.2026. Verfasst von Cheryl Zawadi Kerama und 12 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Diabetes Mellitus (DM) and tuberculosis (TB) interact synergistically. However, glycaemic trajectories in TB are not extensively investigated. TB increases the risk of developing dysglycaemia and while the latter may resolve at the end of treatment, the risk of developing DM for good persists. A diagnosis of DM triples to quadruples the risk of developing TB and the outranks that of TB-HIV co-infection. Most deaths post-TB treatment are cardiovascular (CV) in origin but long-term follow-up for glycaemic monitoring and control in TB, and surrogate biomarkers for CV risk in the context of TB are lacking. Interleukin 18 (IL-18) presents a potential role both as a surrogate biomarker for glycaemia and CV risk prediction. It is a strong predictor of CV risk and death and increase in IL-18 is associated with an increase in risk of CV mortality.
Objectives
To evaluate the performance of markers of glycaemia; glycated haemoglobin (HbA1C) and interleukin 18 (IL 18) as a surrogate biomarker in predicting glycaemic trajectories in patients newly diagnosed with drug-sensitive TB and identify patient factors associated with worsening or persistent trajectories.
Methods
Prospective, nested longitudinal study in Nairobi County, Kenya. Sample size of participants was n=261. Adults with newly diagnosed TB had baseline, month 6 and month 12 HbA1C measured. IL18 was also measured at month 6 and 12 in a subset of participants.
Results
Persons with tuberculosis undergo individualized glycaemic trajectories from diagnosis of TB to the end of treatment that change with time; at month 6 and post-treatment at month 12. The overall rate of diabetes, prediabetes and normoglycaemia at baseline was 28 (10.7%), 102 (39.1%) and 131 (50.2%) respectively. Hyperglycaemia is highest at baseline or start of treatment and begins to decline at the end of treatment and resolves or morphs into a worsening trajectory at month 12. Interleukin-18 levels remain high at the end of treatment at month 6 and at month 12 even in people with a normal HbA1C.
Conclusion
Measurement of IL 18 levels may be a useful surrogate for prediction of CV risk given that people treated with TB have 3 times as much risk of dying than those who have not been treated for it and glycaemic monitoring is needed even after TB treatment.Recommendation: Multi-disciplinary, longer term follow-up post end of treatment at 6 months in drug sensitive tuberculosis is needed to establish those at risk for a worsening glycaemic trajectory and offer personalized glycaemic care for those who persist at diabetes or pre-diabetes. I L-18 level measurement may be a useful surrogate to HbA1C in follow-up of people with TB post-treatment.
Zitieren
APA
Kerama, C. Z., Mureithi, M., Kiplimo, R., Njenga, E., Vezi, B., Mwaura, P., Njoroge, M., Nyadimo, E., Njagi, L., Chacha, R., Ronoh, A., Ong’ang’o, J., & Anzala, O. (2026). Glycaemic trajectories and the role of interleukin 18 as a surrogate biomarker for cardiovascular risk in persons with tuberculosis. Journal of Kenya Assocation of Physicians, 8(1), 13-30. https://doi.org/10.4314/jkap.v8i1.3
Vancouver
Kerama CZ, Mureithi M, Kiplimo R, Njenga E, Vezi B, Mwaura P, et al. Glycaemic trajectories and the role of interleukin 18 as a surrogate biomarker for cardiovascular risk in persons with tuberculosis. Journal of Kenya Assocation of Physicians. 2026;8(1):13-30. doi:10.4314/jkap.v8i1.3
BibTeX
@article{Kerama2026,
author = {Kerama, Cheryl Zawadi and Mureithi, Marianne and Kiplimo, Richard and Njenga, Erick and Vezi, Brian and Mwaura, Patrick and Njoroge, Martha and Nyadimo, Erick and Njagi, Lenis and Chacha, Robi and Ronoh, Aiban and Ong’ang’o, Jane and Anzala, Omu},
title = {Glycaemic trajectories and the role of interleukin 18 as a surrogate biomarker for cardiovascular risk in persons with tuberculosis},
journal = {Journal of Kenya Assocation of Physicians},
year = {2026},
volume = {8},
number = {1},
pages = {13--30},
doi = {10.4314/jkap.v8i1.3}
}
EUVIMED